Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2012

View Archived Issues

Scientists disclose new CD27-targeted candidate immunotherapeutics

GlaxoSmithKline presents highlights of 2011

Novel epithelial sodium channel blockers identified at Novartis

Metal chelators protect against proteins linked to neurodegenerative disorders

New antimicrobials specifically target NAD+-dependent DNA ligases

Antisense Therapeutics provides update on second-generation product

Neuropeptide W/neuropeptide B NPBW1 receptor antagonists described

New candidate cancer immunotherapies developed in France

Merck & Co. reports novel antibacterial immunotherapies

Novel products for hemophilia designed at Novo Nordisk

New bile acid GPBA receptor agonists developed at Roche

U.S. university patents new microRNA-based cancer therapies

Roche reports novel kinase inhibitors

U.S. scientists identify first inhibitors of menin/MLL fusion protein interaction

Alexza Pharmaceuticals receives first feedback on Adasuve MAA

Valeant Pharmaceuticals announces planned acquisition

BioDiem grants exclusive license for LAIV vaccine technology

Advanced Cell Technology treats third patient in phase I/II stem cell study

Celsion kicks off enrollment in ThermoDox trial

Phase III StemEx study is fully enrolled

Karo Bio discontinues development of eprotirome

Amylin Pharmaceuticals launches Bydureon in U.S.

CPP-115 receives European orphan drug status

FDA approves first preservative-free tafluprost ophthalmic solution

FDA grants priority review to Truvada sNDA

Cyclacel reports interim phase II data on sapacitabine in MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...